MX337028B - Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido. - Google Patents

Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido.

Info

Publication number
MX337028B
MX337028B MX2012013689A MX2012013689A MX337028B MX 337028 B MX337028 B MX 337028B MX 2012013689 A MX2012013689 A MX 2012013689A MX 2012013689 A MX2012013689 A MX 2012013689A MX 337028 B MX337028 B MX 337028B
Authority
MX
Mexico
Prior art keywords
serine protease
plasma
removal
treatment
silicon dioxide
Prior art date
Application number
MX2012013689A
Other languages
English (en)
Other versions
MX2012013689A (es
Inventor
Hans-Peter Schwarz
Wolfgang Teschner
Azra Pljevljakovic
Sonja Svatos
Alfred Weber
Ruth Madlener
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337028(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/842,944 external-priority patent/US8304524B2/en
Application filed by Baxter Int filed Critical Baxter Int
Priority claimed from PCT/US2011/038247 external-priority patent/WO2011150284A2/en
Publication of MX2012013689A publication Critical patent/MX2012013689A/es
Publication of MX337028B publication Critical patent/MX337028B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

La presente invención se refiere a nuevos métodos para reducir el contenido de serina proteasas y/o de zimógenos de serina proteasas de una composición de proteínas derivadas de plasma. También se proveen métodos de elaboración de composiciones de proteínas derivadas de plasma con un contenido reducido de serina proteasas y/o de zimógenos de serina proteasas. Entre otros aspectos, la presente invención provee composiciones acuosas y liofilizadas de proteínas derivadas de plasma con un contenido reducido de seria proteasas y/o zimógenos de serina proteasas. Otros aspectos incluyen métodos para tratar, manejar y/o prevenir una enfermedad que comprende la administración de una composición de proteínas derivadas de plasma con un contenido reducido de serina proteasas o de zimógenos de serina proteasas.
MX2012013689A 2010-05-26 2011-05-26 Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido. MX337028B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2010202125A AU2010202125B1 (en) 2010-05-26 2010-05-26 A method to produce an immunoglobulin preparation with improved yield
US12/789,365 US8993734B2 (en) 2010-05-26 2010-05-27 Method to produce an immunoglobulin preparation with improved yield
US12/842,944 US8304524B2 (en) 2009-07-23 2010-07-23 Manufacture of factor H (FH) and FH-derivatives from plasma
PCT/US2011/038247 WO2011150284A2 (en) 2010-05-26 2011-05-26 Removal of serine proteases by treatment with finely divided silicon dioxide

Publications (2)

Publication Number Publication Date
MX2012013689A MX2012013689A (es) 2013-01-28
MX337028B true MX337028B (es) 2016-02-09

Family

ID=42727304

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014006981A MX364252B (es) 2010-05-26 2010-05-27 Método para producir una preparación de inmunoglobulina con un rendimiento mejorado.
MX2012013682A MX349815B (es) 2010-05-26 2010-05-27 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.
MX2012013689A MX337028B (es) 2010-05-26 2011-05-26 Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido.
MX2019004482A MX2019004482A (es) 2010-05-26 2012-11-26 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014006981A MX364252B (es) 2010-05-26 2010-05-27 Método para producir una preparación de inmunoglobulina con un rendimiento mejorado.
MX2012013682A MX349815B (es) 2010-05-26 2010-05-27 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019004482A MX2019004482A (es) 2010-05-26 2012-11-26 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.

Country Status (25)

Country Link
US (6) US8993734B2 (es)
EP (6) EP2554160B1 (es)
JP (6) JP5876474B2 (es)
KR (3) KR101647617B1 (es)
CN (5) CN102970975B (es)
AR (4) AR076800A1 (es)
AU (8) AU2010202125B1 (es)
BR (2) BR112012029893B1 (es)
CA (2) CA2800155A1 (es)
CL (3) CL2012003290A1 (es)
CO (2) CO6660438A2 (es)
DK (3) DK2554160T3 (es)
EA (4) EA034602B1 (es)
ES (4) ES2525492T3 (es)
HK (1) HK1213790A1 (es)
HR (3) HRP20141109T1 (es)
HU (1) HUE064400T2 (es)
IL (2) IL223149A (es)
MX (4) MX364252B (es)
MY (3) MY173299A (es)
PL (4) PL2445482T3 (es)
PT (3) PT2554160E (es)
SG (3) SG185724A1 (es)
TW (3) TWI531577B (es)
WO (1) WO2011149472A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2774053C (en) * 2009-09-17 2015-04-28 Baxter Healthcare, S.A. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
BR112013001753A2 (pt) * 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EP2719704B1 (en) * 2011-04-08 2016-07-20 Universidad De Costa Rica Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
WO2013090636A1 (en) 2011-12-13 2013-06-20 Baxter International Inc. Measurement of autoantibodies at low conductivity conditions with increased sensitivity
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
RU2487725C1 (ru) * 2012-03-15 2013-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) Способ получения концентрированного иммуноглобулинового препарата для подкожного введения
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN103197053B (zh) * 2013-03-15 2015-02-18 上海市血液中心 一种抗IgA抗体检测试剂盒
CN104086646B (zh) * 2014-07-03 2018-10-09 成都蓉生药业有限责任公司 血液制品中fv沉淀的制备方法
CN104086642A (zh) * 2014-07-03 2014-10-08 成都蓉生药业有限责任公司 血液制品中fi+iii上清的制备方法
CN104072601A (zh) * 2014-07-03 2014-10-01 成都蓉生药业有限责任公司 血液制品中fii沉淀的制备方法
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
WO2016064955A1 (en) 2014-10-21 2016-04-28 The General Hospital Corporation Methods of diagnosis and treatment of tuberculosis and infection
CN204424090U (zh) 2014-11-28 2015-06-24 比亚迪股份有限公司 薄膜电容器
WO2016161423A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Process of cloning and further purification to make a recombinant intravenous immunoglobulin
CN107921080A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法
US20160289300A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii
CN108495860A (zh) * 2015-09-29 2018-09-04 K·黄 一种从组分iii制备静脉注射免疫球蛋白的方法
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN106800583A (zh) * 2015-11-26 2017-06-06 上海洲跃生物科技有限公司 一种速溶无析出的冻干人纤维蛋白原制备工艺
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
JP7051132B2 (ja) 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
KR20190053908A (ko) * 2016-09-16 2019-05-20 로이코케어 아게 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법
US11510871B2 (en) 2016-09-16 2022-11-29 Leukocare Ag Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3612221A1 (en) * 2017-04-21 2020-02-26 CSL Behring AG Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy
SG11202003793WA (en) 2017-10-30 2020-05-28 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
DK3728287T3 (da) * 2017-12-19 2024-06-10 CSL Behring Lengnau AG Proteinoprensning og virusinaktivering med alkylglycosider
CN111971302A (zh) * 2018-04-12 2020-11-20 美国安进公司 制备稳定的蛋白质组合物的方法
CN108733099B (zh) * 2018-05-31 2020-08-11 上海药明生物技术有限公司 低pH孵育和中和的自动调节系统及方法
EP4041774A4 (en) * 2019-10-11 2023-03-15 Takeda Pharmaceutical Company Limited HEPARIN INSENSITIVE TEST FOR FACTOR XIA
JP2022553837A (ja) * 2019-11-04 2022-12-26 アルカヘスト，インコーポレイテッド 筋肉再生に使用するための血漿画分
JP2023502412A (ja) * 2019-11-20 2023-01-24 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 沈殿物からタンパク質を抽出する方法および不純物を沈殿させる方法
WO2021202373A1 (en) * 2020-03-31 2021-10-07 Baxalta Incorporated A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
JP2023526738A (ja) * 2020-04-10 2023-06-23 プラズマ テクノロジーズ エルエルシー タンパク質の単純化した高効率単離のための組成物および方法
CN111961130B (zh) * 2020-08-31 2021-09-10 华兰生物工程重庆有限公司 一种从血浆中提取并分离IgM和IgG的方法
WO2022069945A1 (en) * 2020-10-01 2022-04-07 Takeda Pharmaceutical Company Limited Plasma fractionation process utilizing spray-dried human plasma
EP4271706A4 (en) 2020-12-28 2025-01-15 Plasma Technologies LLC SYSTEMS AND METHODS FOR THE ISOLATION OF IMMUNGLOBULIN G ON A PROCESS SCALE
CN112574296B (zh) * 2020-12-30 2023-05-19 中国医学科学院输血研究所 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法
CA3223881A1 (en) 2021-07-29 2023-02-02 Roopsee ANAND Method of purifying immunoglobulin g and uses thereof
US12037360B2 (en) 2021-10-27 2024-07-16 Plasma Technologies, Llc Compositions and methods for isolating proteins
KR102779378B1 (ko) * 2022-01-05 2025-03-12 한양대학교 에리카산학협력단 1-알릴이소크로만 유도체와 이의 제조방법
KR20230121373A (ko) * 2022-02-11 2023-08-18 주식회사 녹십자 인자 xiii의 정제방법
TW202342522A (zh) 2022-03-07 2023-11-01 日商武田藥品工業股份有限公司 臨床人類ｉｇｇ產品之親和層析生產
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
EP4518875A1 (en) 2022-05-02 2025-03-12 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration
KR20250025642A (ko) 2022-06-22 2025-02-24 아제로닉스 에스에이 만성 염증성 탈수초성 다발신경병증과 같은 신경계의 질환 또는 장애의 치료에 사용하기 위한 알파1-항트립신
WO2024200757A1 (en) 2023-03-29 2024-10-03 Csl Behring Ag Methods of identifying immunoglobulin associated with adverse reactions
WO2025008781A1 (en) 2023-07-04 2025-01-09 Csl Behring Ag Method of purification
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
WO2025085544A1 (en) * 2023-10-17 2025-04-24 Plasma Technologies, Llc Integrated process for isolation of plasma proteins
PL448469A1 (pl) * 2024-04-30 2025-11-03 Deveris Polska Spółka Z Ograniczoną Odpowiedzialnością Przedmiotem wynalazku jest sposób wzbogacania preparatów plazmy krwi drobiowej w immunoglobulinę G (IgG)
WO2025229607A1 (en) 2024-05-03 2025-11-06 Csl Behring Ag Systems and methods for solid-liquid separation

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4056614A (en) 1972-09-22 1977-11-01 Marc Bonneau Immunity depressant medicine
US3998946A (en) * 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2801123C2 (de) * 1977-01-26 1986-01-02 Armour Pharma GmbH & Co KG, 3440 Eschwege Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4296027A (en) 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE2902158A1 (de) 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4228154A (en) 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
US4439358A (en) 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3247150A1 (de) 1982-12-21 1984-06-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3523615A1 (de) 1985-07-02 1987-01-15 Cytomed Medizintechnik Medizinisches geraet, insbesondere kanuele, katheter oder implantat
US5061237A (en) 1985-07-02 1991-10-29 Cytomed Medizintechnik Gmbh Method of purifying whole blood
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5136094A (en) 1988-03-10 1992-08-04 Air Products And Chemicals, Inc. Process for the synthesis of secondary formamides
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0440509A3 (en) * 1990-02-02 1991-12-18 Common Services Agency Novel cell growth medium components and process for producing same
DK0447585T4 (da) * 1990-03-22 2003-09-01 Biotest Pharma Gmbh Fremgangsmåde til fremstilling af et intravenøst tolerant immunglobulin-G-præparat
US5130451A (en) * 1991-03-28 1992-07-14 Amoco Corporation Process for preparing carboxyaryl phosphates
US5324425A (en) * 1992-08-26 1994-06-28 Ellison Billy L Method and apparatus for removing solids from aqueous wash solutions
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AUPN858596A0 (en) * 1996-03-08 1996-04-04 Csl Limited Filtration of plasma precipitates using cellulose filter aid
TW491855B (en) * 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5783640A (en) * 1997-03-04 1998-07-21 The Goodyear Tire & Rubber Company Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CN1520885A (zh) 1997-10-23 2004-08-18 ������ҩ��ʽ���� 可室温贮存的免疫球蛋白静脉注射制剂
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AT406873B (de) 1998-02-25 2000-10-25 Immuno Ag Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
AU775149B2 (en) 1999-10-21 2004-07-22 Alcon Inc. Sub-tenon drug delivery
DE10008519C1 (de) 2000-02-21 2001-07-12 Dica Technologies Ag Verfahren und Kommunikationseinrichtungen zum Aufbau von gesicherten E-Mail-Verkehr zwischen Mail-Domains des Internet
DE10008619A1 (de) * 2000-02-24 2001-09-06 Immuno Vet As Lynge Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
JP2004511492A (ja) 2000-10-13 2004-04-15 オクタファルマ　アクチェン　ゲゼルシャフト ビクニンを含む血漿画分、その調製方法、およびその使用
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
MXPA04003156A (es) 2001-10-04 2005-01-25 Protein Therapeutics Inc El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes .
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US7777006B2 (en) * 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
US20050054003A1 (en) 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
WO2005046587A2 (en) 2003-11-08 2005-05-26 Prothera Biologics Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
EP1718675B2 (en) 2004-02-27 2017-01-25 Octapharma AG A method of providing a purified, virus safe antibody preparation
EP2377951A1 (en) 2005-02-14 2011-10-19 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
WO2007038995A1 (en) 2005-09-19 2007-04-12 Csl Behring Gmbh Factor h for the treatment of chronic nephropathies and production thereof
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
KR20080088610A (ko) 2006-01-25 2008-10-02 옥타파르마 아게 상처 치유 지지 인자의 정제와 용도
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP1852443A1 (en) * 2006-05-05 2007-11-07 Leukocare AG Biocompatible three dimensional matrix for the immobilization of biological substances
DE102007001521A1 (de) * 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes
EP2129686B1 (en) 2007-03-20 2016-07-13 CSL Behring GmbH Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
DE202007004346U1 (de) 2007-03-21 2007-10-31 Rehau Ag + Co Rohranordnung
AU2008270951A1 (en) * 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-1 antitrypsin having no significant serine protease inhibitor activity
EP2486936A1 (en) 2007-06-13 2012-08-15 CSL Behring GmbH A composition comprising VWF and FVIII preparations for use in treating of bleeding disorders
AU2008286361B2 (en) 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
AU2008307144B2 (en) * 2007-10-02 2012-12-20 Csl Limited Therapeutic antibody purification method and method of use
TWI600437B (zh) 2007-12-28 2017-10-01 巴克斯歐塔公司 重組ｖｗｆ調配物
CN101249265B (zh) * 2008-04-11 2010-10-27 三九集团湛江开发区双林药业有限公司 静脉注射用人乙肝免疫球蛋白及其制备方法
EP2291654B1 (en) 2008-05-28 2018-04-11 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from blood
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
CN201169579Y (zh) * 2008-06-30 2008-12-24 山东泰邦生物制品有限公司 一种人血白蛋白分离用乙醇雾化扩散装置
HRP20130414T1 (en) 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
CA2742994A1 (en) 2008-11-12 2010-05-20 Baxter International Inc. Purification of butyrylcholinesterase using membrane adsorption
JP5341252B2 (ja) 2009-05-27 2013-11-13 バクスター・インターナショナル・インコーポレイテッド 皮下使用の高濃度免疫グロブリン製剤を生成する方法
AT514675B1 (de) 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
WO2011150284A2 (en) * 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EP3392271B8 (en) 2010-07-08 2021-06-16 Takeda Pharmaceutical Company Limited Method of producing recombinant adamts13 in cell culture
BR112013001753A2 (pt) * 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.

Also Published As

Publication number Publication date
HK1203838A1 (en) 2015-11-06
HK1170168A1 (en) 2013-02-22
JP2017014297A (ja) 2017-01-19
SG10201505161SA (en) 2015-08-28
HRP20150484T1 (hr) 2015-08-14
EP2445482A1 (en) 2012-05-02
CL2014003430A1 (es) 2015-05-04
SG185724A1 (en) 2013-01-30
AU2010224461A1 (en) 2010-10-21
MX2012013682A (es) 2013-01-28
EA025826B1 (ru) 2017-02-28
CN102970975B (zh) 2015-05-06
AR082093A1 (es) 2012-11-14
AU2010202125B1 (en) 2010-09-02
CN109180776B (zh) 2022-12-13
PL2803349T3 (pl) 2024-02-26
TW201202263A (en) 2012-01-16
CN102970975A (zh) 2013-03-13
AU2016202973B2 (en) 2017-12-07
PT2445482E (pt) 2014-11-03
TWI531577B (zh) 2016-05-01
JP2016053016A (ja) 2016-04-14
EP2803349A1 (en) 2014-11-19
AR114228A2 (es) 2020-08-05
CN104958761B (zh) 2021-01-01
ES2525492T3 (es) 2014-12-23
ES2536093T3 (es) 2015-05-20
AU2018201371A1 (en) 2018-03-22
DK2575762T3 (da) 2014-10-13
IL223150A0 (en) 2013-02-03
DK2554160T3 (da) 2015-04-27
TW201542584A (zh) 2015-11-16
HK1215931A1 (zh) 2016-09-30
US11136350B2 (en) 2021-10-05
JP6363676B2 (ja) 2018-07-25
DK2445482T3 (da) 2014-09-22
BR112012029893B1 (pt) 2022-09-06
AR121861A2 (es) 2022-07-20
MX2019004482A (es) 2019-08-30
TW201141879A (en) 2011-12-01
PL2575762T3 (pl) 2015-01-30
WO2011149472A1 (en) 2011-12-01
CA2800155A1 (en) 2011-12-01
AU2021286395A1 (en) 2022-01-20
US20150133644A1 (en) 2015-05-14
JP6592120B2 (ja) 2019-10-16
KR20130080450A (ko) 2013-07-12
PL2554160T3 (pl) 2015-07-31
AU2011258111B2 (en) 2016-02-11
AU2024204779A1 (en) 2024-08-01
EP2554160B1 (en) 2015-02-25
CO6660439A2 (es) 2013-04-30
US8940877B2 (en) 2015-01-27
JP2013528183A (ja) 2013-07-08
EP2803349C0 (en) 2023-09-27
TWI504607B (zh) 2015-10-21
JP2013527201A (ja) 2013-06-27
KR101593265B1 (ko) 2016-02-11
MY173299A (en) 2020-01-14
AU2011258111A1 (en) 2012-12-13
EA023446B1 (ru) 2016-06-30
HRP20140944T1 (hr) 2014-12-05
IL223149A (en) 2017-02-28
PT2554160E (pt) 2015-06-11
EA201291367A1 (ru) 2013-09-30
CL2012003291A1 (es) 2013-10-04
EP2575762A2 (en) 2013-04-10
KR20130109016A (ko) 2013-10-07
CO6660438A2 (es) 2013-04-30
EP2445482B1 (en) 2014-08-27
IL223149A0 (en) 2013-02-03
EP2796128A1 (en) 2014-10-29
EP4039249A1 (en) 2022-08-10
MX349815B (es) 2017-08-09
AU2018201371B2 (en) 2019-10-31
TWI543989B (zh) 2016-08-01
BR112012029897A2 (pt) 2016-08-16
CN104958761A (zh) 2015-10-07
MX364252B (es) 2019-04-17
BR112012029893A2 (pt) 2019-05-28
HK1213790A1 (zh) 2016-07-15
JP5876474B2 (ja) 2016-03-02
HK1181682A1 (en) 2013-11-15
CN109180776A (zh) 2019-01-11
CN103068365B (zh) 2015-07-08
CL2012003290A1 (es) 2013-10-18
JP5866345B2 (ja) 2016-02-17
HK1183449A1 (en) 2013-12-27
EP2575762B1 (en) 2014-07-09
SG185725A1 (en) 2012-12-28
EA034530B1 (ru) 2020-02-18
AR076800A1 (es) 2011-07-06
EA201291355A1 (ru) 2013-04-30
PT2575762E (pt) 2014-07-28
ES2505465T3 (es) 2014-10-10
AU2020200373B2 (en) 2022-01-13
CN103068365A (zh) 2013-04-24
US8993734B2 (en) 2015-03-31
US20210403504A1 (en) 2021-12-30
EA201691558A1 (ru) 2017-05-31
AU2016202973A1 (en) 2016-05-26
KR101716534B1 (ko) 2017-03-14
US20110293638A1 (en) 2011-12-01
ES2959234T3 (es) 2024-02-22
EP2803349B1 (en) 2023-09-27
US20240117009A1 (en) 2024-04-11
CN104840946A (zh) 2015-08-19
KR20160014119A (ko) 2016-02-05
PL2445482T3 (pl) 2015-01-30
US20180118782A1 (en) 2018-05-03
EA201500848A1 (ru) 2016-06-30
MY161617A (en) 2017-04-28
AU2021286395B2 (en) 2024-04-11
HUE064400T2 (hu) 2024-03-28
JP2016155798A (ja) 2016-09-01
US20130101579A1 (en) 2013-04-25
EA034602B1 (ru) 2020-02-25
AU2020200373A1 (en) 2020-02-13
KR101647617B1 (ko) 2016-08-10
CA2800272A1 (en) 2011-12-01
MX2012013689A (es) 2013-01-28
MY160551A (en) 2017-03-15
JP2018080207A (ja) 2018-05-24
HRP20141109T1 (hr) 2014-12-19
AU2010224461B2 (en) 2011-08-04
EP2554160A1 (en) 2013-02-06

Similar Documents

Publication Publication Date Title
MY161617A (en) Removal of serine proteases by treatment with finely divided silicon dioxide
WO2011150284A3 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
EP3486319A3 (en) Compositions and methods comprising serine protease variants
MX339402B (es) Composiciones y metodos que comprenden variantes de serina proteasa.
BR112016005286A2 (pt) composições e métodos compreendendo variantes de protease do clado lg12
NZ601521A (en) Trypsin-like serine protease inhibitors, and their preparation and use
BR112013028440A2 (pt) composições e métodos que compreendem variantes de serina protease
EP3623470A3 (en) Factor ix variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
NZ605871A (en) Treatment of sanfilippo syndrome type b
UA106079C2 (uk) Індукуючі апоптоз засоби для лікування злоякісної пухлини і імунних і аутоімунних захворювань
MX2010002769A (es) Preparacion recombinante de fracciones de bromelaina seleccionadas.
IN2012DN00908A (es)
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
JO2963B1 (en) Reconstructed surfactants with improved properties
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
PH12018502133A1 (en) Conjugated c1 esterase inhibitor and uses thereof
MX2013004906A (es) Nuevos inhibidores especificos de la proteasa ns3 de hcv.
IN2012DN00592A (es)
WO2007132292A3 (en) Therapy for alzheimer's disease
PH12015501131A1 (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
MX350145B (es) Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
MX2009003563A (es) Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
WO2013009844A3 (en) C-3 substituted bicyclooctane based hiv protease inhibitors

Legal Events

Date Code Title Description
FG Grant or registration